ACTG 370:VIROLOGIC & IMMUNOLOGIC ACTIVITY OF CONTINUED LAMIVUDINE VS

仅限核心实验室-样品处理。 最近我们对HIV感染的动态性质和HIV-1复制在疾病发病机制中的重要性的理解取得了进展，再加上新的强效抗逆转录病毒药物如蛋白酶抑制剂的出现，导致了新的治疗模式的发展。 对于大多数患者，需要包括两种逆转录酶（RT）抑制剂和一种蛋白酶抑制剂在内的三种药物方案，以降低和维持HIV-1 RNA的血浆水平低于检测限。 尽管这些方案取得了成功，但由于各种原因可能会发生治疗失败。 本研究探讨了在既往接受过去羟肌苷或d4 T +3 TC治疗的HIV-1 RNA>500 copies/ml的患者中，在加用茚地那韦时，是否应停用拉米夫定或替代非核苷RT抑制剂地拉韦定。

CORE LAB ONLY - SAMPLE PROCESSING. Recent advances in our understanding of the dynamic nature of HIV infection and of the importance of HIV-1 replication in disease pathogenesis, coupled with the advent of new potent antiretroviral agents such as the protease inhibitors, have led to the development of new treatment paradigms. For most patients, three-drug regimens including two reverse transcriptase (RT) inhibitors and a protease inhibitor are needed to reduce and maintain plasma levels of HIV-1 RNA below the limits of detection. Despite the success of these regimens, treatment failures may occur for a variety of reasons. This study addresses the question of whether to discontinue lamivudine or substitute the non-nucleoside RT inhibitor delavirdine when adding indinavir to patients previously treated with didanosine, or d4T plus 3TC who have >500 copies/ml of plasma HIV-1 RNA.